Beta-thalassemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | |||
==References== | ==References== |
Revision as of 22:08, 21 August 2023
Beta-thalassemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Beta-thalassemia cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Beta-thalassemia cost-effectiveness of therapy |
Risk calculators and risk factors for Beta-thalassemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]